Intellect Neurosciences, Inc.

Intellect Neurosciences Inc. (OTCBB: ILNS) is a New York based biopharmaceutical company engaged in the discovery and development of a new breed of innovative “disease-modifying” therapeutic drugs designed to slow, arrest and ultimately prevent Alzheimer's disease and other serious neurological disorders. 

Intellect is focused on proteinopathies, and its pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches, including monoclonal antibodies, antibody drug conjugates and vaccines targeting beta amyloid and abnormal tau proteins. 

Utilizing a streamlined team, Intellect's activities resulted in the development of several drugs, which are now licensed and in advanced clinical trials by large pharmaceutical companies, as well as an extremely valuable IP portfolio that is the envy of many, much larger pharmaceutical companies.  Moreover, Intellect has established a truly pre-eminent international network among foremost industry leaders. 

The company has an internal preclinical and clinical-stage drug pipeline backed by strong intellectual property across the globe and across diversified technologies. Intellect is currently developing three separate platform technologies: 

• ANTISENILIN^® is Intellect’s Alzheimer’s beta amyloid monoclonal antibody platform technology.  The platform provides a method to promote the clearance of amyloid beta toxin away from sites of damage in the brain using highly specific monoclonal antibodies. Such antibodies bind unique molecular signatures at the ends of amyloid beta and do not interfere with either the metabolism or functions of the amyloid precursor protein that has several important functions in the body. One example of monoclonal antibodies exhibiting this property is Bapineuzumab being co-developed by Wyeth/Pfizer and Elan/Johnson & Johnson, and currently being tested in Alzheimer's Phase 3 clinical trials.  The company has granted royalty-bearing licenses to major pharmaceutical companies covering products in late-stage clinical trials that employ the ANTISENILIN platform. 
• RECALL-VAX, the company’s proprietary chimeric peptide vaccine platform for Alzheimer’s and other tauopathies.
• CONJUMAB-A, its antibody drug conjugate platform with potential applications for a broad spectrum of proteinopathies disorders including Alzheimer’s disease, Early-Onset Familial Alzheimer’s disease, cerebral angiopathy, age-related macular degeneration, glaucoma and traumatic brain injury.

The company recently licensed its OX1 technology, a small molecule multimodal antioxidant, to ViroPharma, Inc. for Friedreich’s Ataxia and other neurodegenerative diseases.